Evaluation of rheumatoid factor and anti‐citrullinated peptide antibodies in relation to rheumatological manifestations in patients with leprosy from Southern Brazil

Dionello, Carla da Fontoura; Utiyama, Shirley Ramos da Rosa; Radominski, Sebastião Cézar; Stahlke, Ewalda R S; Stinghen, Sérvio Túlio; Messias-Reason, Iara José de

doi:10.1111/1756-185x.12668

Cited by 10 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hansen disease may show various auto-antibodies such as ANA, anti-dsDNA, anti-cardiolipin antibodies, anti-CCP, and RF. [ 4 , 10 ] The presence of ANA has been reported in 0% to 37.5% of the patients, usually at a low titer, and with speckled and homogenous patterns. [ 11 ] Anti-CCP and RF have significant diagnostic value for RA and have high positive rate, which can be used as the clinical diagnostic evidence of RA.…”

Section: Discussionmentioning

confidence: 99%

Rheumatoid arthritis-like features in Hansen disease

2018

View full text Add to dashboard Cite

Rationale:Hansen disease is an infectious chronic disease with various clinical manifestations. Its joint performance may easily mimic rheumatoid arthritis.Patient concerns:We report a case of a 57-year-old woman diagnosed with Hansen disease 10 years ago, who suffered from joints swelling, pain and joints deformities of both hands for 19 years. The skin on the hands showed rashes, thickening, desquamation and chapping, with both thenar muscles atrophy. She also had severe hypoalgesia of the whole body, and morning stiffness for one hour.Diagnoses:The final diagnosis was joint damage and peripheral neuropathy due to Hansen disease.Interventions:The patient received neurotrophic treatment instead of anti-rheumatic treatment.Outcomes:At 1-year follow up, no further aggravation of joint swelling and pain was detected.Lessons:The correct diagnosis of Hansen disease involving joints depends on the combination of medical history, careful physical examination, and laboratory examination.

show abstract

Section: Discussionmentioning

confidence: 99%

Rheumatoid arthritis-like features in Hansen disease

2018

View full text Add to dashboard Cite

show abstract

“…However, ACPA antibodies are less common in arthritis of leprosy as reported by others. This paper also appears in this issue of IJRD …”

Section: Discussionmentioning

confidence: 88%

“…This paper also appears in this issue of IJRD. 22 The gold standard for diagnosis in cases of arthritis is demonstration of AFB in joints. It is rare to find M. leprae in the joint fluid.…”

Section: Clinical Featuresmentioning

confidence: 99%

Leprosy in the rheumatology clinic: an update on this great mimic

et al. 2016

View full text Add to dashboard Cite

“…The infection caused by M. leprae triggers a relationship between the pathogens and the host, based mainly on immune pathological aspects [19]. Thus, leprosy is an interesting model to investigate the role of the human immune system in the defence of the host and susceptibility to infection [20].…”

Section: Discussionmentioning

confidence: 99%

New therapeutic patents used for the treatment of leprosy: a review

et al. 2018

View full text Add to dashboard Cite

Leprosy is a granulomatous disease, infectious and transmissible, which affects the skin and peripheral nerves, having Mycobacterium leprae as causative agent. The manifestation of this disease causes cutaneous lesions, peripheral neuropathies and, in more extreme cases, may generate deformities and disabilities in affected individuals. Patents were identified using the descriptor 'leprosy' and code A61K of the international patent classification, which indicates only products that meet human needs. The analysis was made using the WIPO, ESPACENET and USPTO databases, until the month of September 2016. Through this review, we found a variety of in vitro, pre-clinical and clinical studies relating to the treatment of leprosy with different types of compounds and forms of administration. New treatment proposals should include pain reduction capabilities, prevention or limitation of the appearance of cutaneous lesions, as well as prevention of the progression of the disease to more severe stages that may lead to loss of function or potentiate the individual's immune response to the M. leprae bacillus in order to prevent bacterial spread. We concluded that any patents developed with natural products were not found in the treatment of leprosy. All the deposited products were synthetic origin, mostly tested in humans and of varied forms of administration.

show abstract

Evaluation of rheumatoid factor and anti‐citrullinated peptide antibodies in relation to rheumatological manifestations in patients with leprosy from Southern Brazil

Abstract: Due to the similarity of some rheumatological manifestations in leprosy with other inflammatory diseases, such as RA, clinical and laboratorial evaluation of affected patients must be carefully assessed in order to achieve proper diagnosis and treatment.

Cited by 10 publications

References 36 publications

Rheumatoid arthritis-like features in Hansen disease

Rheumatoid arthritis-like features in Hansen disease

Leprosy in the rheumatology clinic: an update on this great mimic

New therapeutic patents used for the treatment of leprosy: a review

Contact Info

Product

Resources

About